Literature DB >> 34044866

Integrated transcriptomics explored the cancer-promoting genes CDKN3 in esophageal squamous cell cancer.

Wanpeng Wang1,2, Kai Liao3, Hao Chun Guo4, Suqin Zhou2, Ran Yu2, Yanyan Liu1, Yan Pan5, Juan Pu6,7.   

Abstract

BACKGROUND AND OBJECTIVES: Each individual studies is limited to multi-factors and potentially lead to a significant difference of results among them. The present study aim to explore the critical genes related to the development of Esophageal squamous cell carcinoma (ESCC) by integrated transcriptomics and to investigate the clinical significance by experimental validation.
METHODS: Datasets of protein-coding genes expression which involved in ESCC were downloaded from Gene Expression Omnibus (GEO) database. The "Robustrankaggreg" package in language was used for data integration, and the different expression genes (DEGs) were identified based the cut-off criteria as follows: adjust p-value < 0.05, |fold change (FC)| ≥ 1.5; The protein expression of seed gene in 184 cases of primary ESCC tissues and 50 tumor adjacent normal tissues (at least 5 cm away from the tumor, and defind as the controls) were detected by immunohistochemistry; The relationship between the expression level of seed genes and clinical parameter were analyze. Enumeration data were represented by frequency or percentage (%) and were tested by x2 test. The P value of less than 0.05 was considered statistically significant.
RESULTS: A total of 244 DEGs were identified by comparing gene expression patterns between ESCC patients and the controls based on integrating dataset of GSE77861, GSE77861, GSE100942, GSE26886, GSE17351, GSE38129, GSE33426, GSE20347 and GSE23400; The Cyclin-dependent kinase inhibitor 3 (CDKN3) were identified the top 1 seed gene of top cluster by use of protein-protein Interaction network and plug-in Molecular Complex Detection; The level of CDKN3 mRNA was significantly increased in ESCC patients compared to controls; The positive expression rate of CDKN3 protein in ESCC tissue samples was 32 and 61.4% in control, respectively. The correlations between the expression level of CDKN3 and lymph node metastasis or clinical staging of ESCC patients are statistically significant.
CONCLUSION: Integrated transcriptomics is an efficient approach to system biology. By this procedure, our study improved the understanding of the transcriptome status of ESCC.

Entities:  

Keywords:  Bioinformatics; Cyclin - dependent kinase inhibitor 3 (CDKN3); Esophageal squamous cell carcinoma (ESCC); Integrated transcriptomics; Module mining

Year:  2021        PMID: 34044866     DOI: 10.1186/s13019-021-01534-7

Source DB:  PubMed          Journal:  J Cardiothorac Surg        ISSN: 1749-8090            Impact factor:   1.637


  15 in total

Review 1.  Linear models for microarray data analysis: hidden similarities and differences.

Authors:  M Kathleen Kerr
Journal:  J Comput Biol       Date:  2003       Impact factor: 1.479

2.  MMP1 promotes tumor growth and metastasis in esophageal squamous cell carcinoma.

Authors:  Min Liu; Yi Hu; Mei-Fang Zhang; Kong-Jia Luo; Xiu-Ying Xie; Jing Wen; Jian-Hua Fu; Hong Yang
Journal:  Cancer Lett       Date:  2016-04-26       Impact factor: 8.679

3.  Microarray expression profiling and bioinformatics analysis of circular RNA expression in lung squamous cell carcinoma.

Authors:  Jiali Xu; Yongqian Shu; Tongpeng Xu; Wei Zhu; Tianzhu Qiu; Jun Li; Meiling Zhang; Jing Xu; Renhua Guo; Kaihua Lu; Lingjun Zhu; Yongmei Yin; Yanhong Gu; Lianke Liu; Ping Liu; Rong Wang
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

4.  Weighted Gene Correlation Network Analysis (WGCNA) Detected Loss of MAGI2 Promotes Chronic Kidney Disease (CKD) by Podocyte Damage.

Authors:  Zhi Zuo; Jian-Xiao Shen; Yan Pan; Juan Pu; Yong-Gang Li; Xing-Hua Shao; Wan-Peng Wang
Journal:  Cell Physiol Biochem       Date:  2018-11-16

5.  ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.

Authors:  Hong Ge; Yufei Lu; Yongshun Chen; Xiaoli Zheng; Wen Wang; Jinming Yu
Journal:  Pathol Res Pract       Date:  2014-06-27       Impact factor: 3.250

6.  Investigation into the expression levels of MAGEA6 in esophageal squamous cell carcinoma and esophageal adenocarcinoma tissues.

Authors:  Jun Hao; Shuying Li; Jintao Li; Zhu Jiang; Maliha Ghaffar; Minglian Wang; Runqing Jia; Su Chen; Yangjunqi Wang; Yi Zeng
Journal:  Exp Ther Med       Date:  2019-07-05       Impact factor: 2.447

7.  Phosphatidylinositol 4-phosphate in the Golgi apparatus regulates cell-cell adhesion and invasive cell migration in human breast cancer.

Authors:  Emi Tokuda; Toshiki Itoh; Junya Hasegawa; Takeshi Ijuin; Yukiko Takeuchi; Yasuhiro Irino; Miki Fukumoto; Tadaomi Takenawa
Journal:  Cancer Res       Date:  2014-04-04       Impact factor: 12.701

8.  Robust rank aggregation for gene list integration and meta-analysis.

Authors:  Raivo Kolde; Sven Laur; Priit Adler; Jaak Vilo
Journal:  Bioinformatics       Date:  2012-01-12       Impact factor: 6.937

9.  miR-92b-3p Functions As A Key Gene In Esophageal Squamous Cell Cancer As Determined By Co-Expression Analysis.

Authors:  Wanpeng Wang; Sengwang Fu; Xiaolu Lin; Jinhui Zheng; Juan Pu; Yun Gu; Weijun Deng; Yanyan Liu; Zhongxiang He; Wei Liang; Chengshi Wang
Journal:  Onco Targets Ther       Date:  2019-10-14       Impact factor: 4.147

10.  MAL hypermethylation is a tissue-specific event that correlates with MAL mRNA expression in esophageal carcinoma.

Authors:  Zhe Jin; Liang Wang; Yuan Zhang; Yulan Cheng; Yan Gao; Xianling Feng; Ming Dong; Ziyi Cao; Si Chen; Huimin Yu; Zhenfu Zhao; Xiaojing Zhang; Jie Liu; Yuriko Mori; Xinmin Fan; Stephen J Meltzer
Journal:  Sci Rep       Date:  2013-10-03       Impact factor: 4.379

View more
  1 in total

1.  CDKN3 Overcomes Bladder Cancer Cisplatin Resistance via LDHA-Dependent Glycolysis Reprogramming.

Authors:  Mengxuan Li; Nan Che; Yu Jin; Jinhua Li; Wanshan Yang
Journal:  Onco Targets Ther       Date:  2022-03-26       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.